Microvascular salvage procedures with adjuvant antithrombotic therapy for restitution of patency in a rat model.
Thrombosis following microvascular anastomosis requires further surgical intervention, involving anastomotic resection and reanastomosis or interpositional vein grafting. This study was undertaken to investigate different methods of salvaging thrombosed vessels, using a rat-vein model of error-induced thrombosis. Vessels were reconstructed 4 hr after the onset of thrombosis, using one of three methods: Group 1--removal of the erroneously placed stitch; Group 2--anastomotic resection and re-anastomosis; and Group 3--resection and replacement with a vein graft. Adjuvant antithrombotic therapy was simultaneously evaluated, assessing the influence of systemic Iloprost or heparin. Patency rates at one day postoperatively were 0 percent, 12.5 percent and 37.5 percent for Groups 1, 2, and 3, respectively. Following Iloprost infusion, these rates increased to 25 percent, 25 percent, and 56.3 percent, respectively and, following heparin administration, to 50 percent, 68.8 percent, and 81.8 percent, respectively. Significant increases were found for vein grafting (Group 3), and for the heparin-treated subgroups using all three methods. Effective levels of both Iloprost and heparin were confirmed by increases noted in rat-tail bleeding times. Significant rates of recanalization by three days following one-day occlusion were found in Groups 1 and 2. These results support the application of vein-graft replacement for thrombosed veins, concurrently with systemic heparinization. This study further confirms the high rate of recanalization seen in thrombosed rat femoral veins.
Lan
M
M
Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee 53226.
Li
X L
XL
Cooley
B C
BC
Gould
J S
JS
D000714:Anastomosis, Surgical / Q000009:adverse effects / Q000379:methods*; D000818:Animals; D017024:Chemotherapy, Adjuvant; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D016285:Iloprost / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008866:Microsurgery / Q000009:adverse effects / Q000379:methods; D051381:Rats; D011919:Rats, Inbred Strains; D012086:Reoperation; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control / Q000601:surgery*; D014654:Vascular Patency / Q000187:drug effects*
D005343:Fibrinolytic Agents; D006493:Heparin; D016285:Iloprost